<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362493">
  <stage>Registered</stage>
  <submitdate>5/06/2012</submitdate>
  <approvaldate>22/06/2012</approvaldate>
  <actrnumber>ACTRN12612000672853</actrnumber>
  <trial_identification>
    <studytitle>HiQCell TM Joint Registry in patients with osteoarthritis following the HiQCellTM procedure. 
(This is not a clinical trial - patients undergoing the treatment as prescribed by their specialist are followed up post-procedure.)</studytitle>
    <scientifictitle>A Registry of Autologous Non-Expanded Adipose Derived Stem Cells (HiQCellTM) in the Treatment of Osteoarthritis to determine prevalence of joint infections.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is an observational registry. All patients referred to one of Regeneus HiQCellTM Specialist Centres who have OA in one or more joints who fulfil the inclusion and exclusion criteria are eligible for inclusion. Long-term (5 year) follow up outcomes will be assessed using patient and clinician reported standard questionnaires.</interventions>
    <comparator>No comparator / control treatment as this is an Observational Study</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Confirmed Joint Infections

This will be assessed at the follow up visits with questions from the patients medical specialist on a Post-Op Experience Questionnaire</outcome>
      <timepoint>Post-procedure: 2 weeks, 6 months, 12 months, annually</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Reduction in Pain This will be assessed at baseline (prior to having the HiQCell procedure) and at the follow up visits using validated questionnaires - AQoL, KOOS and NRS</outcome>
      <timepoint>Post-procedure: 2 weeks, 6 months, 12 months, annually</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Impact on Quality of Life This will be assessed at baseline (prior to having the HiQCell procedure) and at the follow up visits with the AQoL and KOOS</outcome>
      <timepoint>Post-procedure: 2 weeks, 6 months, 12 months, annually</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in Analgesic and Anti-inflammatory Use

This will be assessed at baseline &amp; at follow up visits using data collected from the registry on use of Analgesic &amp; Anti-Inflammatory Medication</outcome>
      <timepoint>Post-procedure: 2 weeks, 6 months, 12 months, annually</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Sleep Habits

This will be assessed at baseline &amp; at follow up visits using data collected from the registry on night-time sleeping habits</outcome>
      <timepoint>Post-procedure: 2 weeks, 6 months, 12 months, annually</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Magnetic Resonance Imaging in a subset of knee osteoarthritis

This will be assessed at baseline &amp; at follow up visits using standard radiographic sequences for knees on an MRI scan</outcome>
      <timepoint>Post-procedure: 6months and 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Received a HiQCellTM procedure for joint osteoarthritis
Grade 2, 3 or early Grade 4 Osteoarthritis
Concurrent disease medically stable</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Established Grade 4 osteoarthritis

Major mal-alignment

Large osteophytes

Bone on Bone

Obese

Known allergies/ hypersensitivities to local anaesthetics or antibiotics

Anti-coagulant use (as below) that cannot be stopped or bleeding disorders (no use of Warfarin, Aspirin, Vitamin E, fish oil or anti-inflammatory medications 10 days before treatment)

Immunosuppression
 
Pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/07/2012</anticipatedstartdate>
    <actualstartdate>31/03/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>30/05/2014</actualenddate>
    <samplesize>1000</samplesize>
    <actualsamplesize>403</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>30/05/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>John Flynn - Gold Coast Private Hospital - Tugun</hospital>
    <hospital>The Surgery Centre-Hurstville - Hurstville</hospital>
    <hospital>Macquarie University Hospital - Macquarie Park</hospital>
    <hospital>Linley Clinic - Canterbury</hospital>
    <postcode>4224 - Tugun</postcode>
    <postcode>2220 - Hurstville</postcode>
    <postcode>2113 - Macquarie Park</postcode>
    <postcode>3126 - Canterbury</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Regeneus Ltd</primarysponsorname>
    <primarysponsoraddress>77 Ridge St 
Gordon NSW 2072</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Regeneus Ltd</fundingname>
      <fundingaddress>77 Ridge St 
Gordon NSW 2072</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an observational registry to assess the long-term safety and efficacy of the HiQCell procedure in patients who have been prescribed the procedure to treat joint arthritis following a registered medical specialist consultation.</summary>
    <trialwebsite />
    <publication>Interim data analyses are conducted by the sponsor and made publicly available on the sponsor's website at www.regeneus.com.au. The most recent report, titled 'The HiQCell Joint Registry Interim Report', covers data as of 31-Oct-2014. </publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Bellberry Ltd</ethicname>
      <ethicaddress />
      <ethicapprovaldate>30/05/2012</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>Clinical Research Director - Janet Wilson</name>
      <address>Regeneus Ltd
25 Bridge Street
Pymble NSW 2073 </address>
      <phone>+ 61 2 9499 8010</phone>
      <fax />
      <email>info@regeneus.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Janet Wilson</name>
      <address>Regeneus Ltd
25 Bridge Street
Pymble NSW 2073 </address>
      <phone>61 2 9499 8010</phone>
      <fax />
      <email>info@regeneus.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Clinical Research Director - Janet Wilson</name>
      <address>Regeneus Ltd
25 Bridge Street
Pymble NSW 2073 </address>
      <phone />
      <fax />
      <email>janet.wilson@regeneus.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Jeganath Krishnan</name>
      <address>Orthopaedics SA
Flinders Private Hospital
1 Flinders Drive
Bedford Park SA 5042</address>
      <phone>+61 8 82044289</phone>
      <fax />
      <email>sylvia.mcandrew@flinders.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>